前收市價 | 2.4200 |
開市 | 2.4300 |
買盤 | 2.4100 x 700 |
賣出價 | 2.4400 x 900 |
今日波幅 | 2.4037 - 2.4500 |
52 週波幅 | 1.6400 - 3.1400 |
成交量 | |
平均成交量 | 1,811,793 |
市值 | 924.467M |
Beta 值 (5 年,每月) | 1.01 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -0.1400 |
業績公佈日 | 2024年8月08日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 2.62 |
Before entering the markets, investors need to clearly define their objective. If the idea is to take low-risk and beat inflation, it makes sense to go overweight on blue-chip stocks trading at attractive valuations. If the idea is to generate regular cash flows, investors should be overweight on high dividend yield stocks. Additionally, if the idea is to make massive wealth from the markets, the only way is exposure to millionaire-maker growth stocks. This column focuses on growth stocks to buy
In the middle of a bull market, it is difficult to find good, cheap growth stocks. While you could dig amongst penny stocks to find something to buy, they tend to carry too much risk. More often than not they have a story to tell but no real products or services to sell. Yet raise your sights just a little and you can find growth stocks under $5 that you can buy today. They are accomplished businesses with a proven (or provable) track record. They might not be profitable but there is a clear roa
The performance of cannabis stocks has been underwhelming in the last few years. The reasons include regulatory headwinds, intense competition, and sustained cash burn. However, there finally seems to be light at the end of the tunnel. First, regulatory headwinds seem to be gradually waning. Earlier this year, Germany legalized cannabis for recreational use. Further, the reclassification of cannabis as a Schedule III drug is impending in the United States. It’s also worth noting that some of the